VK Gadi, MD, PhD

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.

Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.

Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.

Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.

Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.

Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.

Vijayakrishna Gadi, MD, PhD, discusses the investigation of AMUN-003 in triple-negative breast cancer.

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.

Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.

Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.

Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.

Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.

Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.

Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.